Veristat to Acquire Certara Unit to Expand CRO Regulatory Capabilities

• Veristat has entered an agreement to acquire Certara’s Regulatory and Medical Writing business, adding more than 200 experts to its CRO platform.

• The deal expands Veristat’s capabilities across regulatory strategy, medical writing, and submission support for complex therapies. 

Veristat announced it has entered into a definitive agreement to acquire Certara’s Regulatory and Medical Writing business, strengthening its position as a full-service contract research organization (CRO) supporting drug development through regulatory submission. The transaction, valued at up to $135 million, is expected to close in the second quarter of 2026. 

The acquisition will add more than 200 regulatory and medical writing professionals to Veristat’s platform, expanding its ability to support clinical trial sponsors across documentation, submission strategy, and regulatory interactions. The incoming team brings experience in authoring clinical and non-clinical documents across the drug development lifecycle. 

From a CRO perspective, the deal enhances Veristat’s integrated service model by combining regulatory writing, biostatistics, and regulatory affairs capabilities under a single platform. The company indicated that this structure is designed to reduce operational fragmentation and support more coordinated submission strategies for complex therapies, including rare diseases and oncology. 

The transaction reflects broader consolidation trends in the CRO and regulatory services market, where sponsors increasingly seek partners capable of managing the full development and submission process without relying on multiple vendors. Expanded in-house expertise is expected to improve efficiency, accelerate timelines, and support regulatory success across global programs. 

“By combining our complementary strengths and talented teams, Veristat will have unmatched capabilities in biostats, medical writing, and regulatory affairs…We will be able to bring even more life-changing medical therapies to patients with unmet needs.”

Kim Boericke, Chief Executive Officer of Veristat